Status:
COMPLETED
Testing the Effectiveness of WW Clinic GLP1
Lead Sponsor:
The Cleveland Clinic
Conditions:
Weight Loss
Obesity
Eligibility:
All Genders
18+ years
Brief Summary
The study objective is to evaluate the efficacy of the WeightWatchers (WW) GLP-1 behavioral program + WW Clinic (formerly known as Sequence medical weight management program) on weight loss and relate...
Detailed Description
This is a 24 week prospective single-arm efficacy outcomes study. Up to 180 adult participants who are currently enrolled in WW GLP-1 behavioral program program + WW Clinic (formerly known as Sequence...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- 18 years or older
- BMI of \>30 or BMI of \>27 with one or more weight related medically qualifying condition (hypertension, dyslipidemia, sleep apnea, cardiovascular disease)
- Access to a smartphone or tablet that runs iOS/iPadOS 15.0 or later, or Android 7.0 or later
- A prescription for Wegovy, Mounjaro, or Zepbound
- Exclusion criteria:
- Diabetes
- Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2
- History of pancreatitis within 180 days
- Previous surgical obesity treatment
- Use of other anti-obesity medication in last 90 days
- Use of GLP-1 within the last 180 days
- Lost weight \>11 lbs in the last 90 days
- Pregnant, breastfeeding, intends to become pregnant, of child-bearing potential and not using a highly effective contraceptive method
Exclusion
Key Trial Info
Start Date :
January 18 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 17 2024
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT06034457
Start Date
January 18 2024
End Date
October 17 2024
Last Update
December 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic
Cleveland, Ohio, United States, 44195